The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 27, 2010
Filed:
Oct. 20, 2005
Carl R. Illig, Phoenixville, PA (US);
Shelley K. Ballentine, Lansdale, PA (US);
Jinsheng Chen, Exton, PA (US);
Sanath Meegalla, Boothwyn, PA (US);
Jonathan Rudolph, Doylestown, PA (US);
Mark J. Wall, Harleysville, PA (US);
Kenneth J. Wilson, West Grove, PA (US);
Renee Desjarlais, Saint Davids, PA (US);
Carl L. Manthey, Downingtown, PA (US);
Christopher M. Flores, Lansdale, PA (US);
Christopher J. Molloy, Yardley, PA (US);
Carl R. Illig, Phoenixville, PA (US);
Shelley K. Ballentine, Lansdale, PA (US);
Jinsheng Chen, Exton, PA (US);
Sanath Meegalla, Boothwyn, PA (US);
Jonathan Rudolph, Doylestown, PA (US);
Mark J. Wall, Harleysville, PA (US);
Kenneth J. Wilson, West Grove, PA (US);
Renee DesJarlais, Saint Davids, PA (US);
Carl L. Manthey, Downingtown, PA (US);
Christopher M. Flores, Lansdale, PA (US);
Christopher J. Molloy, Yardley, PA (US);
Janssen Pharmaceutica NV, , BE;
Abstract
The invention relates to arylamide and hetereoarylamide compounds of Formula I: wherein A, X, Rand W are set forth in the specification, as well as tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.